黑色素瘤特异性抗原基因定量检测在急性髓系白血病及微小残留病监测中的应用

目的 探讨黑色素瘤特异性抗原(PRAME)mRNA在初诊急性髓系白血病(AML)患者中的表达,评估其在微小残留病(MRD)监测中的作用.方法 收集63例初诊AML患者骨髓标本,并在28个月内追踪了11例患者的34份样本,用Taqman探针的荧光定量PCR技术检测PRAME mRNA的表达.结果 初诊患者中PRAME基因表达阳性率52.4 ％(33/63),不同类型的AML中PRAME基因表达以M3最高;治疗缓解后PRAME基因转阴,形态学复发前数月可检测到PRAME mRNA的升高.结论 PRAMEmRNA在AML中高表达,可作为一个广谱的白血病标志物,用于MRD的监测.

Application of quantitative of preferentially expressed antigen of melanoma gene expression in monitoring acute myeloid leukemia and minimal residual disease

Objective To investigate the expression of the preferentially expressed antigen of melanoma (PRAME) gene in acute myeloid leukemia (AML),and to evaluate its applicability in monitoring minimal residual disease (MRD).Methods Bone marrow specimens were collected from 63 cases of de-novo AML,while 34 samples from 11 patients were tracked for 28 months.The level of PRAME mRNA was measured by real time RT-PCR.Results The PRAME gene expressed in 52.4 ％ (33/63) of de-novo patients,and the positive rate was highest in M3 than that in other subtypes of AML.The expression of PRAME became negative after treatment and increased in the following months before morphology relapse.Conclusion The PRAME gene is highly expressed in AML and could be a useful marker to monitor MRD.